Pulmatrix Inc（PULM）股票分析PULMPulmatrix Inc

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Pulmatrix Inc is not a good buy right now due to significant ongoing losses and liquidity concerns, despite a potential merger that could offer future growth. The current price is $1.51, with an RSI of 39.34 indicating a bearish trend. The company has reported a net income loss of $1,172,000 for Q1 2026, and its cash position has decreased from $4.1 million to $3.3 million, raising concerns about operational sustainability. The main risk is the company's negative earnings per share of -0.32 and a forward P/E ratio of 0, indicating no expected profitability in the near term.

1 analysts cover PULM: 1 rate it Buy, 0 Hold and 0 Sell.